I-Mab announces positive outcome in arbitration relating to agreements with Tracon Pharma

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the positive outcome of its arbitration with Tracon Pharmaceuticals (Tracon) relating to (1) the collaboration agreement to co-develop I-Mab